NCT06692166招募中3 期
A Randomized, Open-label, Phase 3 Study to Evaluate 9MW2821 vs Treatment of Physician's Choice in Subjects With Recurrent or Metastatic Cervical Cancer Who Progressed on or After Platinum-based Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 420
- 试验地点
- 2
- 主要终点
- Overall Survival
研究概览
简要总结
The purpose of this study is to compare the efficacy and safety of 9MW2821 and chemotherapy in participants with recurrent or metastatic cervical cancer who progressed on or after platinum-based chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.
- •Female subjects aged 18 to 75 years (including 18 and 75 years).
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Histologically confirmed recurrent or metastatic cervical cancer (squamous cell, HPV-associated adenocarcinoma, or adenosquamous), not amenable to resection or chemoradiation with curative intent.
- •Subject must have received a platinum-based chemotherapy with or without bevacizumab and received no more than 2 prior systemic therapy in the metastatic/recurrent setting. Subject must have experienced radiographic progression during or after the last treatment regimen.
- •An archival tumor tissue sample or a fresh tissue sample should be provided.
- •Life expectancy of ≥ 12 weeks.
- •Subjects must have measurable disease according to RECIST (version 1.1).
- •Adequate to receive one of the chemotherapy regimens in the control group (gemcitabine, pemetrexed, topotecan);
- •Adequate organ functions.
- •Sexually active fertile subjects must agree to use methods of contraception during the study and at least 6 months after termination of study therapy.
- •Subjects are willing to follow study procedures.
排除标准
- •Has other histologies not mentioned as part of the inclusion criteria above, i.e. HPV-independent adenocarcinoma or primary neuroendocrine.
- •Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug, traditional Chinese medicine with anticancer indication within 14 days prior to the first dose of study drug, use of any investigational drug or device within 28 days prior to the first dose of study drug, received treatment of nectin-4 targeted ADC, received treatment of ADC with MMAE payload, received any strong CYP3A4 inhibitors within 14 days prior to the first dose of study drug.
- •Preexisting treatment related toxicity Grade ≥
- •Subjects experienced Grade ≥ 3 immune related adverse events during or after immunotherapy.
- •Subjects had clinically significant hydronephrosis that could not be relieved by nephrostomy or urethral stenting, as determined by the investigator.
- •Major surgery within 28 days prior to first dose of study drug.
- •Hemoglobin A1C (HbA1c) ≥ 8%.
- •Preexisting peripheral neuropathy Grade ≥
- •Any live vaccines within 28 days before first dose of study drug or during the study.
- •Documented history of clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug.
- •Other severe or uncontrolled disease, i.e. severe respiratory system disease, thromboembolic events, active bleeding or active infection.
- •Central nervous system metastases.
- •History of another malignancy within 3 years before the first dose of study drug. Subjects with cured malignancies are allowed.
- •History of autoimmune disease requiring systemic treatment within 2 years before the first dose of study drug.
- •Has ocular conditions that may increase the risk of corneal epithelium damage.
- •Known sensitivity to any of the ingredients of the investigational product; History of drug abuse or mental illness.
- •Uncontrolled tumor-related bone pain or spinal cord compression.
- •Pleural effusion, ascites or pericardial effusion with syptoms or needed drainage.
- •Condition or situation which may put the subject at significant risk.
研究组 & 干预措施
9MW2821
Experimental
干预措施: 9MW2821 (Drug)
Treatment of Physician's Choice
Active Comparator
干预措施: Chemotherapy (Drug)
结局指标
主要结局
Overall Survival
时间窗: Up to 3 years
Time from the date of randomization until the date of death from any cause.
次要结局
- Objective Response Rate per investigator(Up to 3 years)
- Disease Control Rate per investigator(Up to 3 years)
- Progression Free Survival per investigator(Up to 3 years)
- Duration of Response per investigator(Up to 3 years)
- Time to response per investigator(Up to 3 years)
- Incidence of adverse events(Up to 3 years)
- Incidence of Anti-Drug Antibody (ADA)(Up to 3 years)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial CancerAdvanced Urothelial CarcinomaNCT06196736Mabwell (Shanghai) Bioscience Co., Ltd.432
已完成
2 期
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung CancerNon-small Cell Lung CancerSquamous Cell CarcinomaNCT01631357Tianjin Medical University Cancer Institute and Hospital96
已完成
3 期
Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria PatientsFalciparum MalariaNCT00403260Medicines for Malaria Venture1,271
已完成
3 期
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)Chemotherapy-induced Nausea and Vomiting (CINV)NCT00952341Merck Sharp & Dohme LLC421
已完成
3 期
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic CancerPancreatic CancerNCT01926197Stanford University27